Search

Displaying results 5861 - 5870 of 9132 in total
  1. Drug

    Cathinone

    go.drugbank.com/drugs/DB01560
    ExperimentalIllicit

    Cathinone is a monoamine alkaloid found in the shrub Catha edulis (Khat). … Internationally, cathinone is categorized as a Schedule I drug. Cathinone was added to the Controlled Substances Act's Schedule I in 1993 in compliance with international laws.

  2. Drug

    Candoxatrilat

    go.drugbank.com/drugs/DB11623
    Experimental

    A potent inhibitor of neutral endopeptidase (NEP, neprilysin, EC 3.4.24.11), it is used as its 2,3-dihydro-1H-inden-5-yl ester prodrug in the treatment of chronic heart failure. … A dicarboxylic acid monoamide obtained by formal condensation between the amino group of cis-4-aminocyclohexanecarboxylic acid and the cyclopentanecarboxylic acid group of 1-[(2S)-2-carboxy-3-(2-methoxyethoxy

  3. Drug

    Zanidatamab zovodotin

    go.drugbank.com/drugs/DB15472
    Experimental

    According to Zymeworks, "ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as [ZW25] but armed with a cytotoxic payload."

  4. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  5. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

  7. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.

  8. Drug

    Tuxobertinib

    go.drugbank.com/drugs/DB21508
    Investigational

    Tuxobertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Tuxobertinib is a epidermal growth factor receptor (EGFR) inhibitor. … Tuxobertinib has a monoisotopic molecular weight of 560.19 Da.

  9. Drug

    Rimiducid

    go.drugbank.com/drugs/DB04974
    Investigational

    Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer.

  10. Drug

    Efineptakin alfa

    go.drugbank.com/drugs/DB16395
    Investigational

    Efineptakin alfa (also known as NT-I7) is a long-acting human interleukin-7 (IL-7) fusion protein that promotes T-cell development, contributing to the immune response. … Compared to endogenous IL-7, NT-I7 is more stable and potent, has a longer half-life, and has better bioavailability.

    Synonyms: Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc), Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).